J&J Talc Bankruptcy Plan Voided by Court, Reopening Lawsuits; Q1 Revenue Hits $24B, Guidance Raised
JNJ sits 64% above its 52-week low of $146.115.
Summary
A Texas court has voided Johnson & Johnson's Red River Talc bankruptcy plan, a significant legal setback that allows tens of thousands of talc plaintiffs to restart lawsuits against the company. This development introduces substantial uncertainty and potential liabilities, likely overshadowing the positive financial results also reported. Johnson & Johnson announced strong first-quarter 2026 revenue of $24.06 billion, a 9.9% year-over-year increase, and raised its full-year 2026 sales and adjusted EPS guidance. Key drivers included a 68% jump in Tremfya sales and robust growth in Innovative Medicines, particularly oncology. While the financial performance is strong and largely aligns with information from an earlier 8-K, the voiding of the talc bankruptcy plan is new and material, requiring immediate attention from traders. Investors will now focus on J&J's strategy to address the renewed talc litigation risks.
At the time of this announcement, JNJ was trading at $240.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $578.3B. The 52-week trading range was $146.12 to $251.71. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.